BioNTech
BioNTech raises $325M Follow-on Offering at $45B valuation
BioNTech: Follow-on Offering Funding Round
BioNTech has successfully raised $325M in Follow-on Offering funding, reaching a valuation of $45B.
Company Overview
Immunotherapy and mRNA vaccines
Funding Details
The Follow-on Offering round was led by Strüngmann Family Office, with participation from MIG, Salvia, AT Impf, Pfizer.
Company Information
- Headquarters: An der Goldgrube 12, Mainz 55131, Germany
- Founded: 2008
- Employees: 5000+
- Category: Biotech
Investment
BioNTech plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Strüngmann Family Office: Verified investor in Follow-on Offering
- MIG: Verified investor in Follow-on Offering
- Salvia: Verified investor in Follow-on Offering
- AT Impf: Verified investor in Follow-on Offering
- Pfizer: Verified investor in Follow-on Offering
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free